Inhibition of systemic sclerosis dermal fibroblast type I collagen production and gene expression by simvastatin

Arthritis and Rheumatism

Volumn 54, Issue 4, 2006, Pages 1298-1308

  Louneva, Natalia ^a   Huaman, Gonzalo ^a   Fertala, Joanna ^a   Jiménez, Sergio A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT BINDING FACTOR; COLLAGEN TYPE 1; FARNESYL DIPHOSPHATE; GERANYLGERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESSENGER RNA; MEVALONIC ACID; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; SIMVASTATIN;

ARTICLE; CELL FUNCTION; COL1A1 GENE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG CYTOTOXICITY; DRUG EFFECT; ENDOTHELIUM CELL; GEL MOBILITY SHIFT ASSAY; GENE; GENE CONSTRUCT; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; PLEIOTROPY; PRIORITY JOURNAL; PROMOTER REGION; SKIN CULTURE; SKIN FIBROBLAST; SYSTEMIC SCLEROSIS;

CELLS, CULTURED; COLLAGEN TYPE I; FIBROBLASTS; GENE EXPRESSION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; SCLERODERMA, SYSTEMIC; SIMVASTATIN; SKIN;

EID: 33646355930     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21723     Document Type: Article

References (46)

1. Seibold JR. Scleroderma. In: Harris ED, editor. Kelley's textbook of rheumatology. Philadelphia: Elsevier Saunders; 2005. p. 1279-308.
2. Jimenez SA, Hitraya E, Varga J. Pathogenesis of scleroderma: collagen. Rheum Dis Clin North Am 1996;22:647-74.
3. Jimenez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2003;140:37-50.
4. D'Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma): a study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969;46:428-40.
5. Medsger TA Jr. Systemic sclerosis: classification, prognosis. In: Clements PJ, Furst DE, editors. Systemic sclerosis. Philadelphia: Lippincott Williams and Wilkins; 2004. p. 17-28.
6. LeRoy EC. Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. J Clin Invest 1974;54:880-9.
7. Jimenez SA, Feldman G, Bashey RI, Bienkowski R, Rosenbloom J. Co-ordinate increase in the expression of type I and type III collagen genes in progressive systemic sclerosis. Biochem J 1986;237:837-43.
8. Kikuchi K, Smith EA, LeRoy EC, Trojanowska M. Direct demonstration of transcriptional activation of collagen gene expression in systemic sclerosis fibroblasts. Biochem Biophys Res Commun 1992;187:45-50.
9. Hitraya EG, Jimenez SA. Transcriptional activation of the α(I) procollagen gene in systemic sclerosis dermal fibroblasts: role of intronic sequences. Arthritis Rheum 1996;39:1347-54.
10. Hitraya EG, Varga J, Artlett CM, Jimenez SA. Identification of elements in the promoter region of the α1(I) procollagen gene involved in its up-regulated expression in systemic sclerosis. Arthritis Rheum 1998;41:2048-58.
11. Branton MH, Kopp JB. TGF-β and fibrosis. Microbes Infect 1999;1:1349-65.
12. Smith EA, LeRoy EC. A possible role for transforming growth factor-β in systemic sclerosis. J Invest Dermatol 1990;95:125S-7S.
13. Massague J, Wotton D. Transcriptional control by the TGFβ/Smad signaling system. EMBO J 2000;19:1745-54.
14. Attisano L, Wrana JL. Smads as transcriptional co-modulators. Curr Opin Cell Biol 2000;12:235-43.
15. Moustakas A, Heldin CH. Non-Smad TGFβ signals. J Cell Sci 2005;118:3573-84.
16. Rosenbloom J, Saitta B, Gaidarova S, Sandorfi N, Rosenbloom JC, Abrams WR, et al. Inhibition of type I collagen gene expression in normal and systemic sclerosis fibroblasts by a specific inhibitor of geranylgeranyl transferase I. Arthritis Rheum 2000;43:1624-32.
17. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-30.
18. Holstein SA, Wohlford-Lenane CL, Hohl RJ. Consequences of mevalonate depletion. J Biol Chem 2002;277:10678-82.
19. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care. JAMA 2002;288:2998-3007.
20. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al, and the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
21. Derk CT, Jimenez SA. Statins and the vasculopathy of systemic sclerosis: potential therapeutic agents? Autoimmun Rev 2006;5:25-32.
22. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
23. Jimenez SA, Freundlich B, Rosenbloom J. Selective inhibition of human diploid fibroblast collagen synthesis by interferons. J Clin Invest 1984;74:1112-6.
24. Gaidarova S, Jimenez SA. Inhibition of basal and transforming growth factor-β-induced stimulation of COL 1A1 transcription by the DNA intercalators, Mitoxantrone and WP631, in cultured human dermal fibroblasts. J Biol Chem 2002;277:38737-45.
25. Saitta B, Gaidarova S, Cicchillitti L, Jimenez SA. CCAAT binding transcription factor binds and regulates human COL1A1 promoter activity in human dermal fibroblasts: demonstration of increased binding in systemic sclerosis fibroblasts. Arthritis Rheum 2000;43:2219-29.
26. Jimenez SA, Varga J, Olsen A, Li L, Diaz A, Herhal J, et al. Functional analysis of human α1(I) procollagen gene promoter: differential activity in collagen-producing and non-producing cells and response to transforming growth factor-β1. J Biol Chem 1994;269:12684-91.
27. Artlett CM, Chen SJ, Varga J, Jimenez SA. Modulation of basal expression of the human α1(I) procollagen gene (COL 1A1) by tandem NF-1/Sp1 promoter elements in normal human dermal fibroblasts. Matrix Biol 1998;17:425-34.
28. Ghosh AK. Factors involved in the regulation of type I collagen gene expression: implication in fibrosis. Exp Biol Med 2002;227:301-14.
29. Chen SJ, Artlett CM, Jimenez SA, Varga J. Modulation of human α1(I) procollagen gene activity by interaction with Sp1 and Sp3 transcription factors in vitro. Gene 1998;215:101-10.
30. Nehls MC, Grapilon ML, Brenner DA. NF-1/Sp1 switch elements regulated collagen α1(I) gene expression. DNA Cell Biol 1992;11:443-52.
31. Inagaki Y, Truter S, Ramirez F. Transforming growth factor-β stimulates α2(I) collagen gene expression through a cis-acting element that contains an Sp1-binding site. J Biol Chem 1994;269:14828-34.
32. Rossi P, Karsenty G, Roberts AB, Roche NS, Sporn MB, de Crombrugghe B. A nuclear factor 1. binding site mediates the transcriptional activation of a type I collagen promoter by transforming growth factor-β. Cell 1988;52:405-14.
33. Coustry F, Maity SN, Sinha S, de Crombrugghe B. The transcriptional activity of the CCAAT-binding factor CBF is mediated by two distinct activation domains, one in the CBF-B subunit and the other in the CBF-C subunit. J Biol Chem 1996;271:14485-91.
34. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al, for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22.
35. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study(4S). Lancet 1994;344:1383-9.
36. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized controlled trial. Lancet 2002;360:1623-30.
37. Kim SI, Han DC, Lee HB. Lovastatin inhibits transforming growth factor-β1 expression in diabetic rat glomeruli and cultured rat mesangial cells. J Am Soc Nephrol 2000;11:L80-7.
38. Li C, Yang CW, Park JH, Lim SW, Sun BK, Jung JY, et al. Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy. Am J Physiol Renal Physiol 2004;286:F46-57.
39. Goppelt-Struebe M, Hahn A, Iwanciw W, Rehm M, Banas B. Regulation of connective tissue growth factor (ccn2; ctgf) gene expression in human mesangial cells: modulation by HMG CoA reductase inhibitors (statins). Mol Pathol 2001;54:176-9.
40. Holstein SA, Wohlford-Lenane CL, Hohl RJ. Isoprenoids influence expression of Ras and Ras-related proteins. Biochemistry 2002;41:13698-704.
41. Vojtek AB, Der CJ. Increasing complexity of the Ras signaling pathway [review]. J Biol Chem 1998;273:19925-8.
42. Eberlein M, Heusinger-Ribeiro J, Goppelt-Struebe M. Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins). Br J Pharmacol 2001;133:1172-80.
43. Danesh FR, Sadeghi MM, Amro N, Philips C, Zeng L, Lin S, et al. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: implications for diabetic nephropathy. Proc Natl Acad Sci U S A 2002;99:8301-5.
44. Soma MR, Corsini A, Paoletti R. Cholesterol and mevalonic acid modulation in cell metabolism and multiplication. Toxicol Lett 1992;64:1-15.
45. Khanzada UK, Pardo OE, Meier C, Downward J, Seckl MJ, Arcaro A. Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signaling. Oncogene 2005:1-11. E-pub ahead of print.
46. Thibault A, Samid D, Tompkins C, Figg WD, Cooper MR, Hohl RJ, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 1996;2:483-91.